{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:20:39Z","timestamp":1791822039702,"version":"4.3.4"},"reference-count":80,"publisher":"Bentham Science Publishers Ltd.","issue":"4","license":[{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001860"],"award-info":[{"award-number":["UL1 TR001860"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["U54 HD079125"],"award-info":[{"award-number":["U54 HD079125"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPR"],"published-print":{"date-parts":[[2019,12,30]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Fragile X Syndrome (FXS) is the most common cause of inherited intellectual disability\nwith prevalence rates estimated to be 1:5,000 in males and 1:8,000 in females. The increase of\n&gt;200 Cytosine Guanine Guanine (CGG) repeats in the 5\u2019 untranslated region of the Fragile X Mental\nRetardation 1 (FMR1) gene results in transcriptional silencing on the FMR1 gene with a subsequent\nreduction or absence of fragile X mental retardation protein (FMRP), an RNA binding protein\ninvolved in the maturation and elimination of synapses. In addition to intellectual disability,\ncommon features of FXS are behavioral problems, autism, language deficits and atypical physical\nfeatures. There are still no currently approved curative therapies for FXS, and clinical management\ncontinues to focus on symptomatic treatment of comorbid behaviors and psychiatric problems.\nHere we discuss several treatments that target the neurobiological pathway abnormal in FXS. These\nmedications are clinically available at present and the data suggest that these medications can be\nhelpful for those with FXS.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573396315666190625110748","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T05:55:10Z","timestamp":1561528510000},"page":"251-258","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["New Targeted Treatments for Fragile X Syndrome"],"prefix":"10.2174","volume":"15","author":[{"given":"Dragana","family":"Protic","sequence":"first","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Salcedo-Arellano","sequence":"additional","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne Barbara","family":"Dy","sequence":"additional","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Potter","sequence":"additional","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi J.","family":"Hagerman","sequence":"additional","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, Sacramento, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/gm401","volume":"4","author":"Tassone F.","year":"2012","unstructured":"Tassone F.; Iong K.P.; Tong T.H.; \n                        FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med 2012,4(12),100","journal-title":"Genome Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev.neuro.25.112701.142909","volume":"25","author":"O\u2019Donnell W.T.","year":"2002","unstructured":"O\u2019Donnell W.T.; Warren S.T.; A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 2002,25,315-338","journal-title":"Annu Rev Neurosci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"17065","DOI":"10.1038\/nrdp.2017.65","volume":"3","author":"Hagerman R.J.","year":"2017","unstructured":"Hagerman R.J.; Berry-Kravis E.; Hazlett H.C.; Fragile X syndrome. Nat Rev Dis Primers 2017,3,17065","journal-title":"Nat Rev Dis Primers"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s11689-017-9186-9","volume":"9","author":"Erickson C.A.","year":"2017","unstructured":"Erickson C.A.; Davenport M.H.; Schaefer T.L.; Fragile X targeted pharmacotherapy: lessons learned and future directions. J Neurodev Disord 2017,9,7","journal-title":"J Neurodev Disord"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1021\/cn200019z","volume":"2","author":"Healy A.","year":"2011","unstructured":"Healy A.; Rush R.; Ocain T.; Fragile X syndrome: an update on developing treatment modalities. ACS Chem Neurosci 2011,2(8),402-410","journal-title":"ACS Chem Neurosci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1542\/peds.2008-0317","volume":"123","author":"Hagerman R.J.","year":"2009","unstructured":"Hagerman R.J.; Berry-Kravis E.; Kaufmann W.E.; Advances in the treatment of fragile X syndrome. Pediatrics 2009,123(1),378-390","journal-title":"Pediatrics"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s11689-017-9184-y","volume":"9","author":"Schaefer T.L.","year":"2017","unstructured":"Schaefer T.L.; Davenport M.H.; Grainger L.M.; Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1\/2 activation, locomotor behavior, and anxiety. J Neurodev Disord 2017,9,6","journal-title":"J Neurodev Disord"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrd.2017.221","volume":"17","author":"Berry-Kravis E.M.","year":"2018","unstructured":"Berry-Kravis E.M.; Lindemann L.; J\u00f8nch A.E.; Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov 2018,17(4),280-299","journal-title":"Nat Rev Drug Discov"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci8120214","volume":"8","author":"Lee A.W.","year":"2018","unstructured":"Lee A.W.; Ventola P.; Budimirovic D.; Berry-Kravis E.; Visootsak J.; Clinical development of targeted fragile x syndrome treatments: An industry perspective. Brain Sci 2018,8(12)","journal-title":"Brain Sci"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aab4109","volume":"8","author":"Berry-Kravis E.","year":"2016","unstructured":"Berry-Kravis E.; Des Portes V.; Hagerman R.; Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. Sci Transl Med 2016,8(321)","journal-title":"Sci Transl Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/npp.2017.177","volume":"43","author":"Youssef E.A.","year":"2018","unstructured":"Youssef E.A.; Berry-Kravis E.; Czech C.; Effect of the mGluR5-NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double-blind, placebo-controlled Trial: FragXis phase 2 results. Neuropsychopharmacology 2018,43(3),503-512","journal-title":"Neuropsychopharmacology"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/sj.mp.4001167","volume":"7","author":"Chugani D.C.","year":"2002","unstructured":"Chugani D.C.; Role of altered brain serotonin mechanisms in autism. Mol Psychiatry 2002,7(Suppl. 2),S16-S17","journal-title":"Mol Psychiatry"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5582\/irdr.2014.01027","volume":"3","author":"Hanson A.C.","year":"2014","unstructured":"Hanson A.C.; Hagerman R.J.; Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable Rare Dis Res 2014,3(4),110-117","journal-title":"Intractable Rare Dis Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2040-2392-4-16","volume":"4","author":"Boccuto L.","year":"2013","unstructured":"Boccuto L.; Chen C.F.; Pittman A.R.; Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism 2013,4(1),16","journal-title":"Mol Autism"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/280813","volume":"2012","author":"Winarni T.I.","year":"2012","unstructured":"Winarni T.I.; Schneider A.; Borodyanskara M.; Hagerman R.J.; Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome. Case Rep Genet 2012,2012","journal-title":"Case Rep Genet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/DBP.0000000000000334","volume":"37","author":"Greiss Hess L.","year":"2016","unstructured":"Greiss Hess L.; Fitzpatrick S.E.; Nguyen D.V.; A randomized, double-blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome. J Dev Behav Pediatr 2016,37(8),619-628","journal-title":"J Dev Behav Pediatr"},{"key":"ref=17","first-page":"00465","volume":"7","author":"Yoo K.","year":"2017","unstructured":"Yoo K.; Burris J.; Gaul K.; Hagerman R.J.; Rivera S.M.; Low-dose sertraline improves receptive language in children with fragile X syndrome when eye tracking methodology is used to measure treatment outcome. J Psychol Clin Psychiatry 2017,7(6),00465","journal-title":"J Psychol Clin Psychiatry"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ajog.2017.06.003","volume":"217","author":"Romero R.","year":"2017","unstructured":"Romero R.; Erez O.; H\u00fcttemann M.; Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol 2017,217(3),282-302","journal-title":"Am J Obstet Gynecol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","volume":"60","author":"Bailey C.J.","year":"2017","unstructured":"Bailey C.J.; Metformin: historical overview. Diabetologia 2017,60(9),1566-1576","journal-title":"Diabetologia"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"Rena G.","year":"2017","unstructured":"Rena G.; Hardie D.G.; Pearson E.R.; The mechanisms of action of metformin. Diabetologia 2017,60(9),1577-1585","journal-title":"Diabetologia"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2337\/dci15-0013","volume":"39","author":"Song R.","year":"2016","unstructured":"Song R.; Mechanism of metformin: A tale of two sites. Diabetes Care 2016,39(2),187-189","journal-title":"Diabetes Care"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","volume":"20","author":"Foretz M.","year":"2014","unstructured":"Foretz M.; Guigas B.; Bertrand L.; Pollak M.; Viollet B.; Metformin: from mechanisms of action to therapies. Cell Metab 2014,20(6),953-966","journal-title":"Cell Metab"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"Graham G.G.","year":"2011","unstructured":"Graham G.G.; Punt J.; Arora M.; Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011,50(2),81-98","journal-title":"Clin Pharmacokinet"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1734-1140(10)70357-1","volume":"62","author":"\u0141abuzek K.","year":"2010","unstructured":"\u0141abuzek K.; Suchy D.; Gabryel B.; Bielecka A.; Liber S.; Okopie\u0144 B.; Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010,62(5),956-965","journal-title":"Pharmacol Rep"},{"key":"ref=25","first-page":"863","author":"Powers A.","year":"2018","unstructured":"Powers A.; D\u2019Alessio D.; Endocrine Pancreas and Pharmacotherapy of diabetes mellitus and hypoglycemia. Goodman and Gilman\u2019s the pharmacological basis of therapeutics.2018,863-887"},{"key":"ref=26","first-page":"361","author":"Nolte Kennedy M.","year":"2018","unstructured":"Nolte Kennedy M.; Masharanu U.; Pancreatic hormones and antidiabetic drugs. Basic and clinical pharmacology.2018,361-371"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1042\/CS20110386","volume":"122","author":"Viollet B.","year":"2012","unstructured":"Viollet B.; Guigas B.; Sanz Garcia N.; Leclerc J.; Foretz M.; Andreelli F.; Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012,122(6),253-270","journal-title":"Clin Sci (Lond)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev-med-081117-041238","volume":"70","author":"Gantois I.","year":"2019","unstructured":"Gantois I.; Popic J.; Khoutorsky A.; Sonenberg N.; Metformin for treatment of fragile X syndrome and other neurological disorders. Annu Rev Med 2019,70,167-181","journal-title":"Annu Rev Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nm.4335","volume":"23","author":"Gantois I.","year":"2017","unstructured":"Gantois I.; Khoutorsky A.; Popic J.; Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat Med 2017,23(6),674-677","journal-title":"Nat Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/ajmg.a.36023","volume":"161A","author":"Dziembowska M.","year":"2013","unstructured":"Dziembowska M.; Pretto D.I.; Janusz A.; High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 2013,161A(8),1897-1903","journal-title":"Am J Med Genet A"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/DBP.0b013e318287cd17","volume":"34","author":"Leigh M.J.","year":"2013","unstructured":"Leigh M.J.; Nguyen D.V.; Mu Y.; A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr 2013,34(3),147-155","journal-title":"J Dev Behav Pediatr"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"9867","DOI":"10.1523\/JNEUROSCI.1162-14.2014","volume":"34","author":"Sidhu H.","year":"2014","unstructured":"Sidhu H.; Dansie L.E.; Hickmott P.W.; Ethell D.W.; Ethell I.M.; Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci 2014,34(30),9867-9879","journal-title":"J Neurosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.celrep.2014.10.064","volume":"9","author":"Gkogkas C.G.","year":"2014","unstructured":"Gkogkas C.G.; Khoutorsky A.; Cao R.; Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep 2014,9(5),1742-1755","journal-title":"Cell Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/mp.2016.51","volume":"22","author":"Monyak R.E.","year":"2017","unstructured":"Monyak R.E.; Emerson D.; Schoenfeld B.P.; Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model. Mol Psychiatry 2017,22(8),1140-1148","journal-title":"Mol Psychiatry"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/cge.13039","volume":"93","author":"Dy A.B.C.","year":"2018","unstructured":"Dy A.B.C.; Tassone F.; Eldeeb M.; Salcedo-Arellano M.J.; Tartaglia N.; Hagerman R.; Metformin as targeted treatment in fragile X syndrome. Clin Genet 2018,93(2),216-222","journal-title":"Clin Genet"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/BF00915771","volume":"12","author":"Formukong E.A.","year":"1988","unstructured":"Formukong E.A.; Evans A.T.; Evans F.J.; Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 1988,12(4),361-371","journal-title":"Inflammation"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.bjp.0705920","volume":"143","author":"Costa B.","year":"2004","unstructured":"Costa B.; Giagnoni G.; Franke C.; Trovato A.E.; Colleoni M.; Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004,143(2),247-250","journal-title":"Br J Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/sj.bjp.0705587","volume":"141","author":"Costa B.","year":"2004","unstructured":"Costa B.; Colleoni M.; Conti S.; Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 2004,141(1),4-8","journal-title":"Br J Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejp.818","volume":"20","author":"Hammell D.C.","year":"2016","unstructured":"Hammell D.C.; Zhang L.P.; Ma F.; Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain 2016,20(6),936-948","journal-title":"Eur J Pain"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","volume":"38","author":"Morgan C.J.","year":"2013","unstructured":"Morgan C.J.; Das R.K.; Joye A.; Curran H.V.; Kamboj S.K.; Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013,38(9),2433-2436","journal-title":"Addict Behav"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2174\/1570159X15666170724104305","volume":"16","author":"Rapino C.","year":"2018","unstructured":"Rapino C.; Tortolani D.; Scipioni L.; Maccarrone M.; Neuroprotection by (endo)cannabinoids in glaucoma and retinal neurodegenerative diseases. Curr Neuropharmacol 2018,16(7),959-970","journal-title":"Curr Neuropharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18040684","volume":"18","author":"Valdeolivas S.","year":"2017","unstructured":"Valdeolivas S.; Sagredo O.; Delgado M.; Pozo M.A.; Fern\u00e1ndez-Ruiz J.; Effects of a sativex-like combination of phytocannabinoids on disease progression in R6\/2 mice, an experimental model of Huntington\u2019s disease. Int J Mol Sci 2017,18(4)","journal-title":"Int J Mol Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","volume":"263","author":"L\u00f3pez-Send\u00f3n Moreno J.L.","year":"2016","unstructured":"L\u00f3pez-Send\u00f3n Moreno J.L.; Garc\u00eda Caldentey J.; Trigo Cubillo P.; A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease. J Neurol 2016,263(7),1390-1400","journal-title":"J Neurol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","volume":"40","author":"Consroe P.","year":"1991","unstructured":"Consroe P.; Laguna J.; Allender J.; Controlled clinical trial of cannabidiol in Huntington\u2019s disease. Pharmacol Biochem Behav 1991,40(3),701-708","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","volume":"9","author":"Crippa J.A.","year":"2018","unstructured":"Crippa J.A.; Guimar\u00e3es F.S.; Campos A.C.; Zuardi A.W.; Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Front Immunol 2018,9,2009","journal-title":"Front Immunol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/hup.1048","volume":"24","author":"Crippa J.A.","year":"2009","unstructured":"Crippa J.A.; Zuardi A.W.; Mart\u00edn-Santos R.; Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 2009,24(7),515-523","journal-title":"Hum Psychopharmacol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1590\/S1516-44462010000100011","volume":"32","author":"Crippa J.A.","year":"2010","unstructured":"Crippa J.A.; Zuardi A.W.; Hallak J.E.; Therapeutical use of the cannabinoids in psychiatry. Br J Psychiatry 2010,32(Suppl. 1),S56-S66","journal-title":"Br J Psychiatry"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","volume":"25","author":"Crippa J.A.","year":"2011","unstructured":"Crippa J.A.; Derenusson G.N.; Ferrari T.B.; Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol (Oxford) 2011,25(1),121-130","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"Bergamaschi M.M.","year":"2011","unstructured":"Bergamaschi M.M.; Queiroz R.H.; Chagas M.H.; Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients. Neuropsychopharmacology 2011,36(6),1219-1226","journal-title":"Neuropsychopharmacology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2017.00259","volume":"8","author":"Zuardi A.W.","year":"2017","unstructured":"Zuardi A.W.; Rodrigues N.P.; Silva A.L.; Inverted u-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 2017,8,259","journal-title":"Front Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","volume":"39","author":"Zuardi A.W.","year":"2006","unstructured":"Zuardi A.W.; Crippa J.A.; Hallak J.E.; Moreira F.A.; Guimar\u00e3es F.S.; Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006,39(4),421-429","journal-title":"Braz J Med Biol Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","volume":"130","author":"Schubart C.D.","year":"2011","unstructured":"Schubart C.D.; Sommer I.E.; van Gastel W.A.; Goetgebuer R.L.; Kahn R.S.; Boks M.P.; Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011,130(1-3),216-221","journal-title":"Schizophr Res"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"Leweke F.M.","year":"2012","unstructured":"Leweke F.M.; Piomelli D.; Pahlisch F.; Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012,2","journal-title":"Transl Psychiatry"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.02.004","volume":"172","author":"Peres F.F.","year":"2016","unstructured":"Peres F.F.; Diana M.C.; Suiama M.A.; Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia. Schizophr Res 2016,172(1-3),220-221","journal-title":"Schizophr Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"Devinsky O.","year":"2018","unstructured":"Devinsky O.; Patel A.D.; Cross J.H.; Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med 2018,378(20),1888-1897","journal-title":"N Engl J Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","volume":"15","author":"Devinsky O.","year":"2016","unstructured":"Devinsky O.; Marsh E.; Friedman D.; Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016,15(3),270-278","journal-title":"Lancet Neurol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"Devinsky O.","year":"2017","unstructured":"Devinsky O.; Cross J.H.; Laux L.; Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 2017,376(21),2011-2020","journal-title":"N Engl J Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"Thiele E.A.","year":"2018","unstructured":"Thiele E.A.; Marsh E.D.; French J.A.; Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018,391(10125),1085-1096","journal-title":"Lancet"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ajmg.a.32439","volume":"146A","author":"Bailey D.B.","year":"2008","unstructured":"Bailey D.B.; Raspa M.; Olmsted M.; Holiday D.B.; Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A 2008,146A(16),2060-2069","journal-title":"Am J Med Genet A"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11689-010-9067-y","volume":"3","author":"Cordeiro L.","year":"2011","unstructured":"Cordeiro L.; Ballinger E.; Hagerman R.; Hessl D.; Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord 2011,3(1),57-67","journal-title":"J Neurodev Disord"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","volume":"27","author":"Bear M.F.","year":"2004","unstructured":"Bear M.F.; Huber K.M.; Warren S.T.; The mGluR theory of fragile X mental retardation. Trends Neurosci 2004,27(7),370-377","journal-title":"Trends Neurosci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1073\/pnas.90.15.7168","volume":"90","author":"Weiler I.J.","year":"1993","unstructured":"Weiler I.J.; Greenough W.T.; Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc Natl Acad Sci USA 1993,90(15),7168-7171","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1523\/JNEUROSCI.0795-10.2010","volume":"30","author":"Zhang L.","year":"2010","unstructured":"Zhang L.; Alger B.E.; Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci 2010,30(16),5724-5729","journal-title":"J Neurosci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"Bergamaschi M.M.","year":"2011","unstructured":"Bergamaschi M.M.; Queiroz R.H.; Zuardi A.W.; Crippa J.A.; Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011,6(4),237-249","journal-title":"Curr Drug Saf"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","volume":"172","author":"Babalonis S.","year":"2017","unstructured":"Babalonis S.; Haney M.; Malcolm R.J.; Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 2017,172,9-13","journal-title":"Drug Alcohol Depend"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"Iffland K.","year":"2017","unstructured":"Iffland K.; Grotenhermen F.; An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2017,2(1),139-154","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fphar.2017.00081","volume":"8","author":"Sultan S.R.","year":"2017","unstructured":"Sultan S.R.; Millar S.A.; England T.J.; O\u2019Sullivan S.E.; A systematic review and meta-analysis of the haemodynamic effects of cannabidiol. Front Pharmacol 2017,8,81","journal-title":"Front Pharmacol"},{"key":"ref=68","author":"Heussler H.","unstructured":"Heussler H.; Cohen J.; Silove N.; Tich N.; Sebree T.; Siegel S.; Transdermal Cannabidiol (CBD) gel for the treatment of fragile X\nSyndrome (FXS). 57th annual meeting of the American College of Neuropsychopharmacology (ACNP) 2018"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/j.1530-0277.2008.00690.x","volume":"32","author":"Mann K.","year":"2008","unstructured":"Mann K.; Kiefer F.; Spanagel R.; Littleton J.; Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008,32(7),1105-1110","journal-title":"Alcohol Clin Exp Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1111\/j.1530-0277.2002.tb02484.x","volume":"26","author":"Harris B.R.","year":"2002","unstructured":"Harris B.R.; Prendergast M.A.; Gibson D.A.; Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002,26(12),1779-1793","journal-title":"Alcohol Clin Exp Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s10803-010-0988-9","volume":"40","author":"Erickson C.A.","year":"2010","unstructured":"Erickson C.A.; Mullett J.E.; McDougle C.J.; Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord 2010,40(11),1412-1416","journal-title":"J Autism Dev Disord"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/cap.2011.0034","volume":"21","author":"Erickson C.A.","year":"2011","unstructured":"Erickson C.A.; Early M.; Stigler K.A.; Wink L.K.; Mullett J.E.; McDougle C.J.; An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol 2011,21(6),565-569","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5582\/irdr.2016.01046","volume":"5","author":"Salcedo-Arellano M.J.","year":"2016","unstructured":"Salcedo-Arellano M.J.; Lozano R.; Tassone F.; Hagerman R.J.; Saldarriaga W.; Alcohol use dependence in fragile X syndrome. Intractable Rare Dis Res 2016,5(3),207-213","journal-title":"Intractable Rare Dis Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1006\/abbi.1996.0070","volume":"326","author":"Xu X.Q.","year":"1996","unstructured":"Xu X.Q.; McGuire T.F.; Blaskovich M.A.; Sebti S.M.; Romero G.; Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts. Arch Biochem Biophys 1996,326(2),233-237","journal-title":"Arch Biochem Biophys"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.neuron.2012.01.034","volume":"77","author":"Osterweil E.K.","year":"2013","unstructured":"Osterweil E.K.; Chuang S.C.; Chubykin A.A.; Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 2013,77(2),243-250","journal-title":"Neuron"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1002\/ajmg.a.36750","volume":"164A","author":"\u00c7aku A.","year":"2014","unstructured":"\u00c7aku A.; Pellerin D.; Bouvier P.; Riou E.; Corbin F.; Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study. Am J Med Genet A 2014,164A(11),2834-2842","journal-title":"Am J Med Genet A"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/jmg.2008.061796","volume":"46","author":"Bilousova T.V.","year":"2009","unstructured":"Bilousova T.V.; Dansie L.; Ngo M.; Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009,46(2),94-102","journal-title":"J Med Genet"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1242\/dmm.008045","volume":"4","author":"Siller S.S.","year":"2011","unstructured":"Siller S.S.; Broadie K.; Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech 2011,4(5),673-685","journal-title":"Dis Model Mech"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2377-10-91","volume":"10","author":"Paribello C.","year":"2010","unstructured":"Paribello C.; Tao L.; Folino A.; Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010,10,91","journal-title":"BMC Neurol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1352\/1944-7558-115.5.433","volume":"115","author":"Utari A.","year":"2010","unstructured":"Utari A.; Chonchaiya W.; Rivera S.M.; Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 2010,115(5),433-443","journal-title":"Am J Intellect Dev Disabil"}],"container-title":["Current Pediatric Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T10:50:21Z","timestamp":1579863021000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172967\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,30]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573396315666190625110748","relation":{},"ISSN":["1573-3963"],"issn-type":[{"value":"1573-3963","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}